SOPHiA GENETICS SA (SOPH)

Market Cap	356.08M +86.3%
Revenue (ttm)	81.18M +20.9%
Net Income	-80.94M
EPS	-1.18
Shares Out	71.79M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	140,017
Open	4.840
Previous Close	4.780
Day's Range	4.700 - 5.190
52-Week Range	2.590 - 5.700
Beta	0.99
Analysts	Strong Buy
Price Target	8.00 (+61.29%)
Earnings Date	May 5, 2026

About SOPH

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North Americ...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Jul 23, 2021
• Employees: 415
• Stock Exchange: NASDAQ
• Ticker Symbol: SOPH
• Website: https://www.sophiagenetics.com

Financial Performance

In 2025, SOPHiA GENETICS's revenue was $77.27 million, an increase of 18.56% compared to the previous year's $65.17 million. Losses were -$79.00 million, 26.4% more than in 2024.

Analyst Summary

According to 4 analysts, the average rating for SOPH stock is "Strong Buy." The 12-month stock price target is $8.0, which is an increase of 61.29% from the latest price.

Price Target

$8.0

(61.29% upside)

Analyst Consensus: Strong Buy